Impact of stem cell marker expression on recurrence of TACE-treated hepatocellular carcinoma post liver transplantation

BMC Cancer

Zhen Zeng³  Jinyu Ren³  Maura O’Neil⁴  Jie Zhao³  Brian Bridges³  Josiah Cox²  Bashar Abdulkarim¹  Timothy M Schmitt¹  Sean C Kumer¹  Steven A Weinman³ 

[1] Department of Surgery, University of Kansas Medical Center, Kansas City, KS, 66160, USA

[2] Department of Microbiology, University of Kansas Medical Center, Kansas City, KS, 66160, USA

[3] Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS 66160, USA

[4] Department of Pathology, University of Kansas Medical Center, Kansas City, KS, 66160, USA

关键词: Transarterial chemoembolization;    CD44;    CD90;    CD133;    EpCAM;    Cancer stem cells;   

Others  :  1080030
DOI  :  10.1186/1471-2407-12-584

 received in 2012-07-27, accepted in 2012-11-30,  发布年份 2012

【 授权许可】

   
2012 Zeng et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Parkin DM, Bray F, Ferlay J, Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001, 94(2):153-156.
• [2]Ye QH, Qin LX, Forgues M, He P, Kim JW, Peng AC, Simon R, Li Y, Robles AI, Chen Y, et al.: Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 2003, 9(4):416-423.
• [3]Okuda K: Hepatocellular carcinoma. J Hepatol 2000, 32(1 Suppl):225-237.
• [4]Llovet JM, Burroughs A, Bruix J: Hepatocellular carcinoma. Lancet 2003, 362(9399):1907-1917.
• [5]Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L: Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996, 334(11):693-699.
• [6]Hanish SI, Knechtle SJ: Liver transplantation for the treatment of hepatocellular carcinoma. Oncol 2011, 25(8):752-757.
• [7]Chapman WC, Majella Doyle MB, Stuart JE, Vachharajani N, Crippin JS, Anderson CD, Lowell JA, Shenoy S, Darcy MD, Brown DB: Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation. Ann Surg 2008, 248(4):617-625.
• [8]Hanje AJ, Yao FY: Current approach to down-staging of hepatocellular carcinoma prior to liver transplantation. Curr Opin Organ Transplant 2008, 13(3):234-240.
• [9]Yao FY, Kerlan RK Jr, Hirose R, Davern TJ 3rd, Bass NM, Feng S, Peters M, Terrault N, Freise CE, Ascher NL, et al.: Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology 2008, 48(3):819-827.
• [10]Park SJ, Freise CE, Hirose R, Kerlan RK, Yao FY, Roberts JP, Vagefi PA: Risk factors for liver transplant waitlist dropout in patients with hepatocellular carcinoma. Clin Transplant 2012, 26(4):E359-E364.
• [11]Zen C, Zen Y, Mitry RR, Corbeil D, Karbanova J, O'Grady J, Karani J, Kane P, Heaton N, Portmann BC, et al.: Mixed phenotype hepatocellular carcinoma after transarterial chemoembolization and liver transplantation. Liver Transpl 2011, 17(8):943-954.
• [12]Liu LL, Fu D, Ma Y, Shen XZ: The power and the promise of liver cancer stem cell markers. Stem Cells Dev 2011, 20(12):2023-2030.
• [13]Fan ST, Yang ZF, Ho DW, Ng MN, Yu WC, Wong J: Prediction of posthepatectomy recurrence of hepatocellular carcinoma by circulating cancer stem cells: a prospective study. Ann Surg 2011, 254(4):569-576.
• [14]Haraguchi N, Ishii H, Mimori K, Tanaka F, Ohkuma M, Kim HM, Akita H, Takiuchi D, Hatano H, Nagano H, et al.: CD13 is a therapeutic target in human liver cancer stem cells. J Clin Invest 2010, 120(9):3326-3339.
• [15]Yamashita T, Ji J, Budhu A, Forgues M, Yang W, Wang HY, Jia H, Ye Q, Qin LX, Wauthier E, et al.: EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 2009, 136(3):1012-1024.
• [16]Yang ZF, Ngai P, Ho DW, Yu WC, Ng MN, Lau CK, Li ML, Tam KH, Lam CT, Poon RT, et al.: Identification of local and circulating cancer stem cells in human liver cancer. Hepatology 2008, 47(3):919-928.
• [17]Yang ZF, Ho DW, Ng MN, Lau CK, Yu WC, Ngai P, Chu PW, Lam CT, Poon RT, Fan ST: Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell 2008, 13(2):153-166.
• [18]Song W, Li H, Tao K, Li R, Song Z, Zhao Q, Zhang F, Dou K: Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma. Int J Clin Pract 2008, 62(8):1212-1218.
• [19]Ma S, Chan KW, Hu L, Lee TK, Wo JY, Ng IO, Zheng BJ, Guan XY: Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 2007, 132(7):2542-2556.
• [20]Kim H, Choi GH, Na DC, Ahn EY, Kim GI, Lee JE, Cho JY, Yoo JE, Choi JS, Park YN: Human hepatocellular carcinomas with "Stemness"-related marker expression: keratin 19 expression and a poor prognosis. Hepatology 2011, 54(5):1707-1717.
• [21]Shan YF, Huang YL, Xie YK, Tan YH, Chen BC, Zhou MT, Shi HQ, Yu ZP, Song QT, Zhang QY: Angiogenesis and clinicopathologic characteristics in different hepatocellular carcinoma subtypes defined by EpCAM and alpha-fetoprotein expression status. Med Oncol 2011, 28(4):1012-1016.
• [22]Wang B, Jacob ST: Role of cancer stem cells in hepatocarcinogenesis. Genome Med 2011, 3(2):11. BioMed Central Full Text
• [23]Tong CM, Ma S, Guan XY: Biology of hepatic cancer stem cells. J Gastroenterol Hepatol 2011, 26(8):1229-1237.
• [24]Herrera MB, Bruno S, Buttiglieri S, Tetta C, Gatti S, Deregibus MC, Bussolati B, Camussi G: Isolation and characterization of a stem cell population from adult human liver. Stem Cells 2006, 24(12):2840-2850.
• [25]Endo K, Terada T: Protein expression of CD44 (standard and variant isoforms) in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, p53 expression, and patient survival. J Hepatol 2000, 32(1):78-84.
• [26]Yang GH, Fan J, Xu Y, Qiu SJ, Yang XR, Shi GM, Wu B, Dai Z, Liu YK, Tang ZY, et al.: Osteopontin combined with CD44, a novel prognostic biomarker for patients with hepatocellular carcinoma undergoing curative resection. Oncologist 2008, 13(11):1155-1165.
• [27]Yamashita T, Forgues M, Wang W, Kim JW, Ye Q, Jia H, Budhu A, Zanetti KA, Chen Y, Qin LX, et al.: EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res 2008, 68(5):1451-1461.
• [28]Ji J, Yamashita T, Budhu A, Forgues M, Jia HL, Li C, Deng C, Wauthier E, Reid LM, Ye QH, et al.: Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology 2009, 50(2):472-480.